Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
C. Wang S. Dang P. Har D. Mok R. Jayasinghe Empagliflozin has been approved for use in Australia in 2015 for patients with HbA1c ≥7% despite the use of metformin or a sulfonylurea. Despite initially being a medication marketed solely for glycaemic control, EMPA-REG, a landmark trial published in November 2015, demonstrated benefits of empagliflozin in reducing morbidity and mortality in patients with heart failure.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
